当代试验中诱导失败的T细胞急性淋巴细胞白血病儿童及年轻患者的结局
该研究分析2000至2018年间14个协作组治疗的6167例21岁及以下T细胞急性淋巴细胞白血病患者中325例诱导失败者的结局,中位随访6.4年,10年总生存率为54.7%,显著高于历史队列的27.6%。诱导后完全缓解者10年总生存率为59.6%,缓解后接受造血干细胞移植者10年无病生存率显著优于未移植者。
要点
- 诱导失败定义为诱导化疗4-6周后骨髓淋巴母细胞≥5%和/或髓外病变持续存在。
- 当代诱导失败患者10年总生存率为54.7%,显著高于历史队列的27.6%。
- 达到完全缓解者中72%接受移植,其10年无病生存率显著优于未移植者。
核心结论
- 21岁及以下T细胞急性淋巴细胞白血病诱导失败患者当代治疗结局改善,首次缓解期接受造血干细胞移植者有无病生存获益,但结局仍显著落后于诱导结束即缓解者,需研究新治疗方法。
研究设计与样本
- 回顾性分析2000至2018年间14个协作组治疗的6167例21岁及以下T细胞急性淋巴细胞白血病患者,其中325例(5%)诱导失败。
主要发现
- 中位随访6.4年(范围0.3-17.9年),10年总生存率为54.7%(标准误=2.9),显著高于1985至2000年历史队列的27.6%(标准误=2.9)。
- 性别、年龄、白细胞计数、中枢神经系统疾病状态、T细胞成熟度或诱导结束时骨髓疾病负荷对总生存率无显著影响。
- 诱导后93%患者达到完全缓解,其10年总生存率为59.6%(标准误=3.1%),无病生存率为56.3%(标准误=3.1%)。
- 达到完全缓解者中72%接受造血干细胞移植,以190天为界标,移植者10年无病生存率为63.8%(标准误=3.6),显著优于未移植者的45.5%(标准误=7.1)(P=0.005)。
- 移植者10年总生存率为66.2%(标准误=3.6),未移植者为50.8%(标准误=6.8)(P=0.10)。
临床怎么用
- 对于诱导失败的21岁及以下T细胞急性淋巴细胞白血病患者,达到完全缓解后接受造血干细胞移植与无病生存改善相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Historically, patients with T-cell acute lymphoblastic leukemia (T-ALL) who fail to achieve remission at the end of induction (EOI) have had poor long-term survival. The goal of this study was to examine the efficacy of contemporary therapy, including allogeneic hematopoietic stem cell transplantation (HSCT) in first remission (CR1). METHODS: Induction failure (IF) was defined as the persistence of at least 5% bone marrow (BM) lymphoblasts and/or extramedullary disease after 4-6 weeks of induction chemotherapy. Disease features and clinical outcomes were reported in 325 of 6,167 (5%) patients age 21 years and younger treated in 14 cooperative study groups between 2000 and 2018. RESULTS: With a median follow-up period of 6.4 years (range, 0.3-17.9 years), the 10-year overall survival (OS) was 54.7% (SE = 2.9), which is significantly higher than the 27.6% (SE = 2.9) observed in the historical cohort from 1985 to 2000. There was no significant impact of sex, age, white blood cell count, central nervous system disease status, T-cell maturity, or BM disease burden at EOI on OS. Postinduction complete remission (CR) was achieved in 93% of patients with 10-year OS of 59.6% (SE = 3.1%) and disease-free survival (DFS) of 56.3% (SE = 3.1%). Among the patients who achieved CR, 72% underwent HSCT and their 10-year DFS (with a 190-day landmark) was significantly better than nontransplanted patients (63.8% [SE = 3.6] v 45.5% [SE = 7.1]; P = .005), with OS of 66.2% (SE = 3.6) versus 50.8% (SE = 6.8); P = .10, respectively. CONCLUSION: Outcomes for patients age 21 years and younger with T-ALL and IF have improved in the contemporary treatment era with a DFS benefit among those undergoing HSCT in CR1. However, outcomes still lag considerably behind those who achieve remission at EOI, warranting investigation of new treatment approaches.
引用
- Raetz EA, Rebora P, Conter V, et al. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. J Clin Oncol. 2023. PMID: 37487146. doi:10.1200/JCO.23.00088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。